Lilly jumps the gun with Dermira deal
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
Pfizer's abrocitinib heads against Dupixent in atopic dermatitis, while Myovant hopes to raise its Spirits.
Gene therapy’s duration is less than Krystal clear
At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
EADV 2019 – Pfizer carves out a niche for abrocitinib
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Upcoming events – Aurinia and Principia face autoimmune tests
Aurinia hopes to light up with Aurora data, while Principia's BTK inhibitor PRN1008 is put to the test.
Concert squares up to Pfizer in alopecia Jak bout
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Krystal plays down dropout to claim a mid-stage win
Despite concerns about a missing patient, results from a tiny trial in epidermolysis bullosa boosted Krystal Biotech’s stock by 41%.
Upcoming events – Novartis and Miragen hope for heartening data
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
